An AMPS LLC Magazine

The AMPS Insider is a quarterly magazine dedicated to all AMPS' partners and customers. Published by AMPS, it provides news and information about AMPS' products and initiatives.

#12 - 4Q2023

Executive Overview

The ISCE 48th Annual Conference. Ventricular tachycardia and in-hospital mortality in the intensive care unit. Product news. AMPS People.

Editorial

We are happy to announce the <u>48th Annual Conference</u> of the International Society of Computerized Electrocardiology (<u>ISCE</u>).

The meeting will take place at Chateau Elan, Braselton, Georgia (just north of Atlanta metropolitan area) from Wednesday, April 3 through Sunday, April 7, with an exciting program that will cover different areas of cardiovascular research and technology, such as Pediatric Cardiology, Consumer electronics and ECG devices and Machine Learning in automated ECG analysis. As a member of the Board of Trustees, AMPS will be well represented, starting with our President and Chief Scientist Fabio Badilini, who also serves as the President of ISCE, plus members of our engineering team. More information about the meeting, including registration instructions, can be found here.

We are also happy to introduce a manuscript recently published on Heart Rhythm O²: Ventricular tachycardia and in-hospital mortality in the intensive care unit.

The paper reports the outcomes of a large annotation effort led by the UCSF Center for Physiologic Research, and involves an international group of notable scientists. The main finding is an increased rate of 30-day in-hospital mortality from intensive care unit patients associated with well-validated events of ventricular tachycardia. This is an important clinical contribution which re-establishes the importance of ventricular tachycardia as a mortality risk factor in bedside monitoring.

The full article can be read on the AMPS web site

Products News

AMPS is historically committed to providing its pharma customers software solutions that cover all facets and market requirements for cardiac drug development. Currently AMPS is exploring a new telemetry platform specifically designed for early-phase, first-in-human clinical sites. This solution targets the replacement of similar existing products that are being phased out of production and no longer supported thereby helping to meet the changing needs of this industry. Throughout 2023, AMPS has engaged and met with a broad set of stakeholders, contributing to the collection of comprehensive requirements which will help to design a software-centric platform capable of addressing existing market gaps, while remaining adaptable to address future technical challenges in the conduction of clinical trials.

As a part of this project, AMPS has reached an agreement with Global Instrumentation (GI), a leading manufacturer of 12-lead ECG device and data management technology for telemetry workflow that will contribute to the project success. The GI contribution can provide critical components for the development and the manufacture of a multi-purpose 12-lead ECG transmitter. The product characteristics and target availability dates shall be announced during the coming year.


The team completed the development of ECGCor and BPCor, which are two tools designed for the analysis of resting ECGs and continuous blood pressure monitoring respectively and intended for both standalone use and for integration with telemedicine applications. These products have been submitted for certification as CE Medical Devices by the Italian Subsidiary CardioCalm.

We are pleased to offer you the magazine free of charge. Feel free to download an article, or even an entire issue. These are available in PDF format for your convenience. All the articles are copyrighted, so we ask that you not publish or distribute for profit any of the articles without express written permission from AMPS.

A new product is also being designed and developed: "EAT", the *Ecg Anonymizer Tool*. Data privacy is of the utmost importance in healthcare so to satisfy the growing requests from the industry to comply with the laws and regulations to protect the confidentiality of medical records, which applies also to ECG data collected in clinical trials, AMPS is developing this new tool that accepts input ECG data from all the existing AMPS supported ECG formats and returns as output the ECG stripped of any demographic data.

AMPS People

We are very pleased to announce that Antonello Racsan, after completing his Computer Engineering thesis work at the University of Brescia, will join the AMPS team in 2024. Antonello is passionate about technology innovation, web communication protocols, and will contribute to the development of the AMPS telecardiology platform.



Antonello Racsan

Advertisement

Troubles with your ecg data?? AMPS can help you!

- * Conversion of ecg paper traces (or scanned images) into digital HL7 FDA xml ecg files
- * Conversion of proprietary digital ecg files formats into the HL7 FDA xml ecg format
- ❖ Validation of HL7 FDA xml ecg and continuous recording ecg files prior to submission to the FDA ECG Warehouse
- ❖ Submission of HL7 FDA xml ecg files to the FDA ECG Warehouse
- Secondary analysis of already submitted or halted studies by performing state-of-the-art analysis such as: HRV, Holter Bin, Beat to Beat (B2B).

For further information or questions please contact: AMPS.Services@amps-llc.com